Skip to content
Sequencing Therapy in Relapsed/Refractory Myeloma Patients
Selecting the Best Frontline Therapy for Transplant Eligible Myeloma Patients
Novel Advances in Myelofibrosis: Diagnosis-Risk Stratification-Therapy
Acquired Inhibitors in Cancer: State-of-the Art Management
Novel Therapeutic Strategies for MDS Based on Molecular Profile
CAR-T Cell Therapy in Lymphomas: 7-Years Later
De Novo Acute Myeloid Leukemia
Targeted Therapy in Hema Malignancies (CD20, CD30, CD33, BCR/ABL, FLT3, IDH1/2)
CLL: Therapeutic Advances in 2024
Navigating Mantle Cell Lymphoma in the Era of Targeted Therapy
What Is New for DLBCL and & Hodgkin’s Disease?
Novel Advances in T-Cell NHL Therapies
Small Cell Lung Cancer: Targeting This Difficult Target
Non Driver NSCLC: The Immunotherapy Strategy
Other Driver Mutations: ROS-1, BRAF, MET and RET
ALK: First Line and Mechanism Of Resistance
EGFR Exon 20 Insertions: Novel Agents
What Is Next After Osimertinib Progression?
Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy
Adjuvant Therapies in NSCLC
Optimal Surgical Approach in Early Stages NSCLC
Screening in Lung Cancer: Challenges and Obstacles
Challenges in Lung Cancer Pathology: Biomarkers
ctDNA in Lung Cancer: Current State and Future Perspectives
